Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.

MLA

Rice, Lisa M., et al. “Fresolimumab Treatment Decreases Biomarkers and Improves Clinical Symptoms in Systemic Sclerosis Patients.” The Journal of Clinical Investigation, vol. 125, no. 7, July 2015, pp. 2795–807. EBSCOhost, https://doi.org/10.1172/JCI77958.

APA

Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., Spiera, R. F., Christmann, R. B., Gordon, J. K., Weinberg, J., Simms, R. W., & Lafyatis, R. (2015). Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. The Journal of Clinical Investigation, 125(7), 2795–2807. https://doi.org/10.1172/JCI77958

Chicago

Rice, Lisa M, Cristina M Padilla, Sarah R McLaughlin, Allison Mathes, Jessica Ziemek, Salma Goummih, Sashidhar Nakerakanti, et al. 2015. “Fresolimumab Treatment Decreases Biomarkers and Improves Clinical Symptoms in Systemic Sclerosis Patients.” The Journal of Clinical Investigation 125 (7): 2795–2807. doi:10.1172/JCI77958.